SCHEME 1. Synthetic Strategy
New Strategy for the Synthesis of Substituted
Morpholines
Matthew L. Leathen, Brandon R. Rosen, and John P. Wolfe*
Department of Chemistry, UniVersity of Michigan, 930 North
UniVersity AVenue, Ann Arbor, Michigan, 48109-1055
SCHEME 2. Synthesis of Substrates
ReceiVed April 6, 2009
a Ligand ) (o-biphenyl)PtBu2. b Ligand ) P(tBu)3 ·HBF4. c Ligand )
(()-BINAP.
We recently reported a concise asymmetric synthesis of cis-
2,6-disubstituted piperazines that involves Pd-catalyzed car-
boamination reactions of N-allyl ethylenediamine derivatives.6,7
We felt that a similar strategy may be applied to the construction
of 3,5-disubstituted morpholines. As shown in Scheme 1,
enantiopure N-Boc amino alcohols (1) could be converted to
O-allyl ethanolamines 2 using standard methods. These com-
pounds would then be transformed to the desired heterocycles
3 through Pd-catalyzed coupling with an aryl or alkenyl halide.8
This strategy should provide access to a broad array of
enantiopure cis-3,5-disubstituted morpholines that are difficult
to generate using existing methods.
The substrates for the Pd-catalyzed carboamination reactions
were synthesized in three steps from commercially available
starting materials 1a-e as shown in Scheme 2. Treatment of
the N-protected amino alcohols with NaH and allyl bromide
afforded allyl ethers 4a-e. Cleavage of the Boc-group followed
by Pd-catalyzed N-arylation of the resulting amine trifluoroac-
etate salts provided 2a-f in moderate to good yield.9
A four-step synthesis of cis-3,5-disubstituted morpholines
from enantiomerically pure amino alcohols is described. The
key step in the synthesis is a Pd-catalyzed carboamination
reaction between a substituted ethanolamine derivative and
an aryl or alkenyl bromide. The morpholine products are
generated as single stereoisomers in moderate to good yield.
This strategy also provides access to fused bicyclic mor-
pholines as well as 2,3- and 2,5-disubstituted products.
In recent years drug discovery efforts have revealed several
interesting biologically active compounds that contain C-
substituted morpholine units.1,2 However, despite the medicinal
importance of these molecules, the development of new ap-
proaches to their synthesis remains relatively unexplored.1,3 For
example, few methods allow the preparation of 3,5-disubstituted
morpholines,4 and only two approaches to the stereoselective
synthesisofcis-3,5-disubstitutedderivativeshavebeendescribed.2a,5
Both of these strategies are limited in scope, as one affords
symmetrically disubstituted (meso) products5 and the other was
used only for the generation of one single compound (cis-3-
carbomethoxy-5-allylmorpholine).2a
At the beginning of our studies we elected to examine the
coupling of 2c with 2-bromotoluene under reaction conditions
(4) For stereoselective syntheses of trans-3,5-disubstituted morpholines, see:
(a) Leijondahl, K.; Boren, L.; Braun, R.; Ba¨ckvall, J.-E. Org. Lett. 2008, 10,
2027. (b) Dave, R.; Sasaki, N. A. Tetrahedron: Asymmetry 2006, 17, 388. (c)
Dave, R.; Sasaki, N. A. Org. Lett. 2004, 6, 15. (d) Takahata, H.; Takahashi, S.;
Kouno, S.-i.; Momose, T. J. Org. Chem. 1998, 63, 2224. For non-stereoselective
syntheses of 3,5-disubstituted morpholines, see: (e) Revesz, L.; Blum, E.; Wicki,
R. Tetrahedron Lett. 2005, 46, 5577. (f) Enders, D.; Meyer, O.; Raabe, G.;
Runsink, J. Synthesis 1994, 66. (g) Barluenga, J.; Najera, C.; Yus, M. Synthesis
1978, 911.
(5) D’hooghe, M. D.; Vanlangendonck, T.; To¨rnroos, K. W.; De Kimpe, N.
J. Org. Chem. 2006, 71, 4678.
(6) (a) Nakhla, J. S.; Wolfe, J. P. Org. Lett. 2007, 9, 3279. (b) Nakhla, J. S.;
Schultz, D. M.; Wolfe, J. P. Tetrahedron 2009, in press, DOI:, 10.1016/
j.tet.2009.04.017.
(7) For related syntheses of pyrrolidines, imidazolidin-2-ones, isoxazolidines,
and pyrazolidines via Pd-catalyzed carboamination reactions, see: (a) Ney, J. E.;
Wolfe, J. P. Angew. Chem., Int. Ed. 2004, 43, 3605. (b) Bertrand, M. B.; Neukom,
J. D.; Wolfe, J. P. J. Org. Chem. 2008, 73, 8851. (c) Fritz, J. A.; Wolfe, J. P.
Tetrahedron 2008, 64, 6838. (d) Lemen, G. S.; Giampietro, N. C.; Hay, M. B.;
Wolfe, J. P. J. Org. Chem. 2009, 74, 2533. (e) Giampietro, N. C.; Wolfe, J. P.
J. Am. Chem. Soc. 2008, 130, 12907.
(1) For a review on the synthesis and biological significance of C-substituted
morpholines, see: Wijtmans, R.; Vink, M. K. S.; Schoemaker, H. E.; van Delft,
F. L.; Blaauw, R. H.; Rutjes, F. P. J. T. Synthesis 2004, 641.
(2) For selected examples of biologically active cis-3,5-disubstituted mor-
pholines, see: (a) O’Neil, S. V.; Wang, Y.; Laufersweiler, M. C.; Oppong, K. A.;
Soper, D. L.; Wos, J. A.; Ellis, C. D.; Baize, M. W.; Bosch, G. K.; Fancher,
A. N.; Lu, W.; Suchanek, M. K.; Wang, R. L.; De, B.; Demuth, T. P., Jr. Bioorg.
Med. Chem. Lett. 2005, 15, 5434. (b) Allison, B. D.; Phuong, V. K.; McAtee,
L. C.; Rosen, M.; Morton, M.; Prendergast, C.; Barrett, T.; Lagaud, G.; Freedman,
J.; Li, L.; Wu, X.; Venkatesan, H.; Pippel, M.; Woods, C.; Rizzolio, M. C.;
Hack, M.; Hoey, K.; Deng, X.; King, C.; Shankley, N. P.; Rabinowitz, M. H.
J. Med. Chem. 2006, 49, 6371. (c) Josien, H. B.; Clader, J. W.; Bara, T. A.; Xu,
R.; Li, H.; Pissarnitski, D.; Zhao, Z. Chem. Abstr. 2006, 144, 129004 PCT Int.
Appl. WO 2006004880 A2, January 12, 2006;
(3) For recent approaches to the synthesis of C-substituted morpholines, see:
(a) Yar, M.; McGarrigle, E. M.; Aggarwal, V. K. Org. Lett. 2009, 11, 257. (b)
Penso, M.; Lupi, V.; Albanese, D.; Foschi, F.; Landini, D.; Tagliabue, A. Synlett
2008, 2451. (c) Wilkinson, M. C.; Bell, R.; Landon, R.; Nikiforov, P. O.; Walker,
A. J. Synlett 2006, 2151. (d) Lanman, B. A.; Myers, A. G. Org. Lett. 2004, 6,
1045. (e) Tiecco, M.; Testaferri, L.; Marini, F.; Sternativo, S.; Santi, C.; Bagnoli,
L.; Temperini, A. Tetrahedron: Asymmetry 2003, 14, 2651.
(8) For reviews on Pd-catalyzed carboamination reactions, see: (a) Wolfe,
J. P. Eur. J. Org. Chem. 2007, 571. (b) Wolfe, J. P. Synlett 2008, 2913.
10.1021/jo9007223 CCC: $40.75 2009 American Chemical Society
Published on Web 06/01/2009
J. Org. Chem. 2009, 74, 5107–5110 5107